Rapport Therapeutics, Inc. (RAPP)
Last updated: 2026-10-21 22:29:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Rapport Therapeutics, Inc. (RAPP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $25.02, with a market capitalization of $1.37B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $23.75 to $52.93. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.37B | |
$29.91 | |
$52.93 | |
$6.43 | |
$29.37 | |
2.02M | |
476.80K | |
-- | |
$52.93 | |
$23.75 | |
-- | |
-- |
Rapport Therapeutics, Inc. (RAPP) After-Hours Stock Price
Rapport Therapeutics, Inc. (RAPP) is trading at $25.96 in after-hours trading as of 2026-10-21 22:27:00, down 11.63% ($3.42) from the regular-session close of $29.37.
After-hours trading shows how investors are pricing RAPP after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Rapport Therapeutics, Inc. (RAPP) 7-Day Stock Price Change
Over the past seven days, Rapport Therapeutics, Inc. (RAPP) moved from $30.15 to $25.02, representing a decline of 17.01% ($5.13).
The stock traded between $24.76 and $31.31 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.43 million shares, up versus the previous seven-day period, indicating higher trading activity.
RAPP 52-Week Price Position
Position in Range: 4.4%
RAPP is currently trading at $25.02, placing it 4.4% of the way from its 52-week low of $23.75 to its 52-week high of $52.93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Rapport Therapeutics, Inc. (RAPP)?
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Rapport Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 84 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Rapport Therapeutics, Inc. (RAPP) Stock on MEXC
Eligible investors can buy real shares of Rapport Therapeutics, Inc. (RAPP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Rapport Therapeutics, Inc. (RAPP) stock price today?
2.Is RAPP stock going up or down today?
3.What is RAPP pre-market price?
4.What is RAPP after-hours price?
5.Is RAPP stock trading now?
6.Where does RAPP sit relative to its 52-week high and low?
7.What sector is Rapport Therapeutics, Inc. in?
8.What is Rapport Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is RAPP valued in terms of P/E ratio and EPS?
10.Does Rapport Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
RAPP Stock Calculator
Estimate the value between RAPP shares and USD.
RAPP Shares to USD
1.00 RAPP shares = 25.021 USD
Calculations are estimates based on the latest available price and are for reference only.


